

CVnCoV [233]	Cure Vac AG	RNA	I Recruiting	Prevention	A randomized, sequential assignment, single masked trial N = 168 Study start date: June 18, 2020	Belgium/ Germany
SCB-2019 [234]	Cliver Biopharmaceuticals AUS Pty Ltd	Protein Subunit	I Recruiting	Prevention	A randomized, sequential assignment, triple masked trial N = 150 Study start date: June 19, 2020	Australia
COVAX-19 vaccine [235]	Vaxine Pty Ltd	Protein Subunit	I Recruiting	Prevention	A randomized, parallel assignment, triple masked trial N = 40 Study start date: June 30, 2020	Australia
V-SARS [236]	Immunitor LLC	Inactivated	I/II Active, not recruiting	Treatment	An interventional, single group assignment for treatment of COVID-19 with pill N = 20 Study start date: May 15, 2020	Canada/ Mongolia
LV-SMENP-DC [237]	Shenzhen Geno-Immune Medical Institute	Lentiviral	I/II Recruiting	Treatment	An interventional, single group assignment for treatment of COVID-19 with novel lentiviral-based DC and T cell vaccines N = 100 Study start date: March 24, 2020	China
BNT162 [238]	BioNTech/ Pfizer	RNA	I/II Ongoing	Treatment	A non-randomized, sequential assignment trial to test the effect of four different BNT162 vaccines against COVID-19 in healthy individuals N = 200 Study start date: April 23, 2020	Germany
aAPC vaccine [239]	Shenzhen Geno-Immune Medical Institute	Lentiviral	I Recruiting	Treatment	An open-label, single-group assignment N = 100 Study start date: February 15, 2020	China